Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PLRZ
- Company Polyrizon Ltd.
- Price $10.91
- Changes Percentage -24.73
- Change -3.5861
- Day Low $10.33
- Day High $14
- Year High $7200
- Year Low $2.88
- Market Cap $10,624,522
- Price Avg 50 EMA (D) $5.96
- Price Avg 200 EMA (D) $247.86
- Exchange NASDAQ
- Volume 1,651,376
- Average Volume 3,122,303
- Open $12.57
- Previous Close $14.5
- EPS -1.22
- PE -8.89
- Earnings Announcement 1970-01-01 00:00:00
- Shares Outstanding $980,122
Company brief: POLYRIZON LTD. (PLRZ )
- Healthcare
- Biotechnology
- Mr. Tomer Izraeli
- https://www.polyrizon-biotech.com
- IL
- N/A
- 10-29-2024
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
PLRZ Corporation News
What Sparked Polyrizon's (PLRZ) 140% After-Hours Stock Surge?
feeds.benzinga.com -- Polyrizon surged in nearly 140% after-hours trading following preclinical data showing its naloxone hydrogel outperforms a marketed spray and a key manufacturing milestone....
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
globenewswire.com -- Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra'anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ...
